A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects.

Trial Profile

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs NNC 0165-1562 (Primary)
  • Indications Obesity
  • Focus Adverse reactions; First in man
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 10 Feb 2017 Status changed from recruiting to completed.
    • 31 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
    • 31 May 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top